Background: Programmed cell death-ligand 1 (PD-L1) immunohistochemical expression currently is the only approved useful biomarker associated with the PD-1/PD-L1 immune checkpoint blockade (ICB) ...

Abstract: TPS (Tumor Proportion Score) serves as a crucial indicator to determine the eligibility of cancer patients for PD-L1 immunohistochemistry (IHC) treatment. In clinical practice, pathologists ...

Cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy in advanced NSCLC with high PD-L1 expression. The EMPOWER-Lung 1 trial showed a median OS of ...

Background: Immunotherapy plays a crucial role in the treatment of tumors. However, few studies have investigated the relationship between the expression of Programmed Cell Death Ligand 1 (PD-L1, ...

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization. At the 2025 ESMO Gynecological ...

1Key Laboratory of Dunhuang Medicine and Transformation at Provincial and Ministerial Level, Gansu University of Chinese Medicine, Lanzhou, China. 2Provincial-Level Key Laboratory for Molecular ...

NEW ORLEANS—A first-in-class peptide-based PET tracer, 18 F-AlF-NOTA-PCP2, can effectively measure PD-L1 expression in patients with head and neck cancers, outperforming the conventional tracer 18 ...

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...

This project is based on the Multiple Instance Learning (MIL) method and predicts the expression of the PD-L1 gene by analyzing H&E (hematoxylin-eosin) stained slice images in histopathology. Based on ...